DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES

DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES

The paper analyzes the key biological effects of cytokines that play a central role in the pathogenesis of immunoinflammatory rheumatic diseases. Special attention is drawn to major proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-17. There are data fr...

Full description

Bibliographic Details
Main Authors:	E. L. Nasonov, V. I. Mazurov, Yu. V. Usacheva, E. V. Chernyaeva, Ya. Yu. Ustyugov, A. B. Ulitin, R. A. Ivanov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2017-04-01
Series:	Научно-практическая ревматология
Subjects:	anti-il-17 monoclonal antibodies anti-il-6 receptor monoclonal antibodies bispecific anti-tnf-α and anti-il-17 monoclonal antibodies
Online Access:	https://rsp.mediar-press.net/rsp/article/view/2364

Similar Items

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
by: Lazaros I. Sakkas, et al.
Published: (2019-08-01)

IL-17 is a Potential Therapeutic Target in a Rodent Model of Otitis Media with Effusion
by: Zhang N, et al.
Published: (2022-02-01)

From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment
by: Silvia Vidal, et al.
Published: (2021-06-01)

Targeting IL-23 in psoriasis: current perspectives
by: Fotiadou C, et al.
Published: (2018-01-01)

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis
by: Fernando Valenzuela, et al.
Published: (2021-10-01)

Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR
by: V. I. Mazurov, et al.
Published: (2023-03-01)

Takayasu’s Arteritis Diagnosed in an Adolescent Patient with Crohn’s Disease: Management of Biologicals
by: Kazuya Kishimoto, et al.
Published: (2021-09-01)

Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study
by: V. I. Mazurov, et al.
Published: (2021-05-01)

New Approaches in Immunotherapy of Behçet Disease
by: Behzad Baradaran, et al.
Published: (2013-02-01)

Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
by: Chuchu Zhang, et al.
Published: (2021-11-01)

Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis
by: Eugenia Veronica Di Brizzi, et al.
Published: (2023-10-01)

The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
by: Bader Bashrahil, et al.
Published: (2023-01-01)

Toward a molecular understanding of adaptive immunity:A chronology, Part II
by: Kendall A Smith
Published: (2012-11-01)

Anti-IL5/IL5R Treatment in COPD: Should We Target Oral Corticosteroid-Dependent Patients?
by: Laroche J, et al.
Published: (2023-05-01)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
by: Erin Bartholomew, et al.
Published: (2023-09-01)

Artritis reumatoide, epidemiología, fisiopatología, criterios diagnósticos y tratamiento
by: D. Gamero García
Published: (2018-09-01)

Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review
by: Alexandra Norden, et al.
Published: (2022-11-01)

Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis
by: A. A. Kubanov, et al.
Published: (2019-07-01)

Anti-IL-17A antibody-associated de novo vitiligo: Case report and review of literature
by: Hsing-Jou Su, et al.
Published: (2023-01-01)

The study of pharmacodynamics of a medicine based on humanized monoclonal antibodies against IL-17 in rabbit model of antigen-induced arthritis
by: A. A. Nedorubov, et al.
Published: (2018-02-01)

Unexpected liaisons between old cytokines and new deadly virus
by: Alberto Beretta
Published: (2020-07-01)

A prospective study exploring the predictors of response to benralizumab in patients with refractory bronchial asthma
by: Masahiro Hirose, et al.
Published: (2022-02-01)

Interleukin-5 mediates peritoneal eosinophilia induced by the F1 cell wall fraction of Histoplasma capsulatum
by: A. Sá-Nunes, et al.
Published: (2004-03-01)

Autoimmunity in human CE: Correlative with the fertility status of the CE cyst
by: Saftawy E. A. EL, et al.
Published: (2022-05-01)

Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018-01-01)

The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
by: Maria V. Deligiorgi, et al.
Published: (2021-10-01)

Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients
by: Han Cao, et al.
Published: (2021-02-01)

A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers
by: Tracy L. Staton, et al.
Published: (2019-01-01)

PREPARATION AND PROPERTIES OF MURINE ANTI-IDIOTYPIC MONOCLONAL ANTIBODIES RECOGNIZING PRIMARY RABBIT POLYCLONAL ANTIBODIES AGAINST MORPHINE DERIVATIVES
by: A. V. Trofimov, et al.
Published: (2019-12-01)

Bispecific antibodies and their use in applied research
by: Harshit Verma, et al.
Published: (2012-01-01)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017-11-01)

Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis
by: Logan W. Thomas, et al.
Published: (2019-02-01)

Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety
by: M. T. Corasaniti, et al.
Published: (2023-12-01)

Large-scale production of monoclonal antibodies in suspension culture /
by: 271860 Backer, M. P., et al.

Potential gastrointestinal Behcet’s disease flare after treatment with anti-interleukin 17a therapy
by: Frances Sze Kei Sun, et al.
Published: (2023-08-01)

Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis
by: Eugenia Piragine, et al.
Published: (2022-03-01)

Risankizumab as an effective therapeutic option in severe psoriasis unsuccessfully treated with therapies involving anti- TNF-α and anti-IL-17
by: Michał Adamczyk, et al.
Published: (2020-10-01)

Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial
by: Luis Puig, et al.
Published: (2021-10-01)

Severe pediatric asthma therapy: Dupilumab
by: Giuliana Ferrante, et al.
Published: (2022-11-01)

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
by: Ruggiero A, et al.
Published: (2022-06-01)